188 related articles for article (PubMed ID: 15801830)
1. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Toogood PL; Harvey PJ; Repine JT; Sheehan DJ; VanderWel SN; Zhou H; Keller PR; McNamara DJ; Sherry D; Zhu T; Brodfuehrer J; Choi C; Barvian MR; Fry DW
J Med Chem; 2005 Apr; 48(7):2388-406. PubMed ID: 15801831
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
6. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
8. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
[TBL] [Abstract][Full Text] [Related]
9. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
10. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
16. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Reddy MV; Akula B; Cosenza SC; Athuluridivakar S; Mallireddigari MR; Pallela VR; Billa VK; Subbaiah DR; Bharathi EV; Vasquez-Del Carpio R; Padgaonkar A; Baker SJ; Reddy EP
J Med Chem; 2014 Feb; 57(3):578-99. PubMed ID: 24417566
[TBL] [Abstract][Full Text] [Related]
18. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
[TBL] [Abstract][Full Text] [Related]
19. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
[TBL] [Abstract][Full Text] [Related]
20. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
